「or」の検索結果
87件：36～40件目を表示
-
CATALIN_TE_C3_20220805
剤、pH調節剤 びまん性表層角膜炎、結膜充血、結膜炎、刺 激感、そう痒感、霧視、眼脂、流涙、眼痛、 眼の異常感、眼の異物感 眼瞼炎、接触皮膚炎 頻度不明 過敏症 眼 放射能濃度 （ng eq./mL or g） 10 0 0 6 12 18 24 時間 （h） 20 房水 水晶体 図 ウサギに0.005%3H-ピレノキシン点眼液を 点眼投与後の眼組織中放射能濃度 ＊2022年11月改訂 （第 2 ...
https://www.senju.co.jp/system/files/product_other_file/2022-09/CATALIN_TE_C3_20221101.pdf -
chida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
al Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 S...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
24 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -
24 Senju Pharmaceutical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509_0.pdf